Replies to post #3762 on Generex Biotechnology Corp. (fka GNBTQ)

[hotelbar]

My brother says maybe gnbt didnt pay off the rite people in the fda or a bigger company paid the fda not to look at gnbt's results. Lol

[zumoney]

I too wonder about Oralyn in the u.s.

Recently Mannkind had progress with their ph3 inhaled insulin, Afrezza. Their stock had a bunch of movement.

To me, Oralyn sounds better because it is not deposited in the lungs. It absorbs in the upper respiratory or actually oral cavity/throat. Whereas other companies (Pfizer from what I understand) failed because products deposited further down had encountered complications with the patients. Also, MNKD had issues with Afrezza in the past. As I understand they had to submit requests a few times and were getting rejected for various things earlier?

Oralyn in India was going to be approved earlier until they required an in country study before they would review data. Apparently that is what the hold up was and the delay for the last few years. Seems that things are getting closer with Oralyn there.

Overall it seems that oral insulins have a ton of hurdles to get past. Not an easy road for any maker. Hence why attempts were given up by others. I feel that overall it is easier to produce the injectable insulins even though inhaled would definitely be better for the patient.

Regardless, I am crossing my fingers for GNBT. AE37 can be huge. immunotherapies will be king when it comes to treating cancer in the coming years. More and more with each year. Just who will get there faster and more successfully? Large variety of approaches and all these new IPOs this year promising new drugs. i vote for GNBT as they are already well invested into the whole deal. Big money, big money, no whammie, no whammie!!!